Olumiant OverviewBaricitinib (trade name Olumiant) is a drug for the treatment of rheumatoid arthritis (RA), being developed by Incyte and Eli Lilly. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved in Europe. Contents 1 Approvals and indications 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 History 6.1 Clinical trials 6.2 Approval process 7 See also 8 References ...
Read more Olumiant Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Baricitinib
Recent Olumiant Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 2mg
NDC Database Records for Olumiant: (1 result)Sorted by National Drug Code
- 0002-4182 Olumiant 2 mg Oral Tablet, Film Coated by Eli Lilly and Company